Kassner Nina, Wonnemann Meinolf, Ziegler Yvonne, Stange Rainer, Kostev Karel
Repha GmbH Biologische Arzneimittel, 30855 Langenhagen, Germany.
Department for Internal and Integrative Medicine, Immanuel Hospital, 10117 Berlin, Germany.
Antibiotics (Basel). 2024 Oct 17;13(10):982. doi: 10.3390/antibiotics13100982.
The goal of this study was to evaluate whether the medical recommendation of Angocin (heretofore referenced as Angocin) on the day of diagnosis of acute bronchitis is negatively associated with the recurrence of acute bronchitis diagnosis, antibiotic prescriptions, incidence of chronic bronchitis, and duration of sick leave.
This study included patients in general practices in Germany with a first documented diagnosis of acute bronchitis between 2005 and 2022 (index date) and a prescription of Angocin, thyme products, essential oils, mucolytics or antibiotics on the index date. The association between Angocin prescription and the risks of a relapse of acute bronchitis, development of chronic bronchitis, or subsequent antibiotic prescription were evaluated using Cox regression models. Univariable conditional logistic regression models were used to investigate the association between Angocin prescription and duration of sick leave.
After a 1:5 propensity score matching, 598 Angocin patients and 2990 patients in each of the four comparison cohorts were available for analysis. Angocin prescription was associated with significantly lower incidence of a renewed confirmed diagnosis of acute bronchitis as compared to essential oils (Hazard ratio (HR): 0.61; 95% Confidence Interval (CI): 0.46-0.80), thyme products (HR: 0.70; 95% CI: 0.53-0.91), mucolytics (HR: 0.65; 95% CI: 0.49-0.85) or antibiotics (HR: 0.64; 95% CI: 0.49-0.84). Also, there were significantly lower incidences of subsequent re-prescriptions of antibiotics when compared to mucolytics (HR: 0.73; 95% CI: 0.53-0.99) or antibiotics (HR: 0.53; 95% CI: 0.39-0.72) and a significantly lower risk of chronic bronchitis as compared to essential oils (HR: 0.60; 95% CI: 0.46-0.78), thyme products (HR: 0.53; 95% CI: 0.41-0.69), mucolytics (HR: 0.49; 95% CI: 0.38-0.63) or antibiotics (HR: 0.59; 95% CI: 0.45-0.76).
Considering the limitations of the study, the results shed light on the sustaining effectiveness of Angocin prescription in the management of acute bronchitis and the associated outcomes when compared to several other treatments commonly used for this condition.
本研究的目的是评估在急性支气管炎诊断当天使用安哥辛（以下简称安哥辛）的医疗建议是否与急性支气管炎诊断的复发、抗生素处方、慢性支气管炎的发病率以及病假时长呈负相关。
本研究纳入了2005年至2022年期间（索引日期）在德国普通诊所首次确诊为急性支气管炎且在索引日期开具了安哥辛、百里香产品、精油、黏液溶解剂或抗生素处方的患者。使用Cox回归模型评估安哥辛处方与急性支气管炎复发风险、慢性支气管炎发展或后续抗生素处方之间的关联。使用单变量条件逻辑回归模型研究安哥辛处方与病假时长之间的关联。
经过1:5倾向评分匹配后，有598名安哥辛患者以及四个对照队列中各2990名患者可供分析。与精油（风险比（HR）：0.61；95%置信区间（CI）：0.46 - 0.80）、百里香产品（HR：0.70；95% CI：0.53 - 0.91）、黏液溶解剂（HR：0.65；95% CI：0.49 - 0.85）或抗生素（HR：0.64；95% CI：0.49 - 0.84）相比，安哥辛处方与再次确诊急性支气管炎的发生率显著降低相关。此外，与黏液溶解剂（HR：0.73；95% CI：0.53 - 0.99）或抗生素（HR：0.53；95% CI：0.39 - 0.72）相比，后续再次开具抗生素的发生率也显著降低，并且与精油（HR：0.60；95% CI：0.46 - 0.78）相比慢性支气管炎风险显著降低，与百里香产品（HR：0.53；95% CI：0.41 - 0.69）、黏液溶解剂（HR：0.49；95% CI：0.38 - 0.63）或抗生素（HR：0.59；95% CI：0.45 - 0.76）相比慢性支气管炎风险也显著降低。
考虑到本研究的局限性，研究结果揭示了与其他几种常用于治疗急性支气管炎的方法相比，安哥辛处方在急性支气管炎管理中的持续有效性以及相关结果。
